Is Editas stock a good buy?
Out of 7 analysts, 2 (28.57%) are recommending EDIT as a Strong Buy, 2 (28.57%) are recommending EDIT as a Buy, 2 (28.57%) are recommending EDIT as a Hold, 0 (0%) are recommending EDIT as a Sell, and 1 (14.29%) are recommending EDIT as a Strong Sell.
Who invested in Editas?
With an initial investment of $43 million from Flagship Ventures, Polaris Partners and Third Rock Ventures, Editas will use the new $120 million funding to translate the CRISPR/Cas9 technology into genomic medicines to treat diseases including cancers, sickle-cell anemia, retinal disease, and Duchenne muscular …
Why is Editas stock down?
Some investors could be concerned about a threat from CRISPR base editing. However, the main factor behind Editas’ decline this week appears to be the overall sell-off in biotech stocks.
Who owns Editas medicine?
Editas Medicine
| Type | Public |
|---|---|
| Founders | Jennifer Doudna, Feng Zhang, George Church (geneticist), David R. Liu, J. Keith Joung |
| Headquarters | Cambridge, Massachusetts , United States |
| Number of locations | 2 |
| Key people | James Mullen (President and CEO) |
What does Editas medicine do?
Editas Medicine is a leading genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of medicines for people living with serious diseases around the world.
Should I invest in CRSP?
The financial health and growth prospects of CRSP, demonstrate its potential to underperform the market. It currently has a Growth Score of F. Recent price changes and earnings estimate revisions indicate this would not be a good stock for momentum investors with a Momentum Score of F.
Who is the CEO of Editas medicine?
James C Mullen (Feb 15, 2021–)Editas Medicine / CEO
Who are the founders of Editas?
Jennifer Doudna
Feng ZhangGeorge ChurchJ. Keith JoungDavid R. Liu
Editas Medicine/Founders
Is Beam Therapeutics a good buy?
If early interim data that Beam Therapeutics posts a couple of years from now doesn’t appear competitive with CTX001, the stock could take a tumble. While this is a top gene-editing stock to watch, it’s still a little too risky to buy right now.
Will edit stock go up?
Editas Medicine Inc (NASDAQ:EDIT) The 14 analysts offering 12-month price forecasts for Editas Medicine Inc have a median target of 27.50, with a high estimate of 80.00 and a low estimate of 10.00. The median estimate represents a +149.55% increase from the last price of 11.02.
Why did doudna leave Editas?
Doudna left Editas a few weeks after the patent was granted. She says she had family commitments at home in Berkeley and was tired of traveling to Cambridge but adds, “You’re welcome to draw your own conclusions.” A year later, she became a “cofounder” of Intellia—based in Cambridge.
What does Editas mean?
Informal second-person singular (tú) present indicative form of editar.